Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer

Roberts, Kate; Rickett, Kirsty; Vagenos, Dimitrios; Woodward, Natasha

doi:10.1002/14651858.cd012988

Cited by 5 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Around half of BCS on Ais experience AIMS, significantly impacting their quality of life (Grigorian & Baumrucker, 2022). In addition, AIMS decreases adherence rates to AI therapy in approximately half of BCS, in turn compromising survival rate (Roberts et al, 2020; Singer et al, 2012).…”

Section: Altered Somatosensory Functioning In Breast Cancer Survivors...mentioning

confidence: 99%

Altered somatosensory functioning and mechanism‐based classification in breast cancer patients with persistent pain

Haenen

Dams

Groef

2022

The Anatomical Record

View full text Add to dashboard Cite

Pain is one of the most frequent and persistent side effects of breast cancer treatment. Besides pain, breast cancer survivors (BCS) are prone to experience a myriad of other signs and symptoms related to altered somatosensory function, including for example, hypoesthesia, allodynia, and hyperalgesia, both at the local site of cancer and in remote body parts. Different breast cancer treatments can have a direct effect on somatosensory functioning, resulting in a wide range of these signs and symptoms. To our knowledge, currently no comprehensive overview exists on altered somatosensory functioning and resulting signs and symptoms in BCS with persistent pain. Investigating altered somatosensory functioning in this population could provide more insights in the underpinning pathophysiological mechanisms and consequently improve prevention and treatment in the future. Therefore, in this paper, first, normal somatosensory functioning is described. Second, quantitative sensory testing is presented as the recommend method to evaluate somatosensory functioning. Third, existing evidence on altered somatosensory functioning in BCS with persistent pain is summarized. Altered somatosensory functioning related to the most common cancer treatment modalities, including surgery and radiotherapy, hormone therapy, and chemotherapy are discussed. In addition, evidence on the presence of nociplastic pain as pain resulting from altered somatosensory functioning without evidence for nociception and/or neuropathy in BCS is summarized. At last, a discussion on this available evidence, limitations, and perspectives for clinical practice and for research are made.

show abstract

Section: Altered Somatosensory Functioning In Breast Cancer Survivors...mentioning

confidence: 99%

Altered somatosensory functioning and mechanism‐based classification in breast cancer patients with persistent pain

Haenen

Dams

Groef

2022

The Anatomical Record

View full text Add to dashboard Cite

show abstract

“…Breast cancer is a serious public health problem and the leading cause of death among women 1,2 . According to the latest statistics from the World Health Organization (WHO), breast cancer accounts for 10% of all types of cancers and 6.5% of global mortality 3 .…”

Section: Introductionmentioning

confidence: 99%

A systematic review of recommendations on screening strategies for breast cancer due to hereditary predisposition: Who, When, and How?

et al. 2021

View full text Add to dashboard Cite

BackgroundBreast cancer is a global health problem that cannot be underestimated. Many studies have shown that breast cancer is related to pathogenic mutations in hereditary predisposition genes. Clinical practice guidelines play a vital role in guiding the selection of breast cancer screening. Little is known about the quality and consistency of guidelines’ recommendations and their changes over these years.MethodsWe reviewed the existing screening guidelines for genetic susceptibility to breast cancer and assessed the methodological quality, and summarized the recommendations to aid clinicians to make decisions. We conducted a systematic search in PubMed, Embase, Web of Science, and guideline‐specific databases, aiming to find the guidelines of breast cancer due to hereditary predisposition. The necessary information was exacted by Excel. We also summarized different evidence grading systems. The qualities of the guidelines were assessed by the Appraisal of Guidelines Research and Evaluation II (AGREE II) instrument.ResultsA total of 54 recommendations from 13 guidelines were extracted. Generally speaking, the recommendations were consistent, mainly focusing on mammography and MRI.ConclusionsThe recommendations differ in details. Moreover, different guidelines are based on different grading systems, and some guidelines are not divided for age limits, which may limit the promotion and implementation of the guidelines. It is suggested that improvement can be made in this regard in the future.

show abstract

Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer

Roberts

Rickett

Chatfield

et al. 2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer

Cited by 5 publications

References 24 publications

Altered somatosensory functioning and mechanism‐based classification in breast cancer patients with persistent pain

Altered somatosensory functioning and mechanism‐based classification in breast cancer patients with persistent pain

A systematic review of recommendations on screening strategies for breast cancer due to hereditary predisposition: Who, When, and How?

Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer

Contact Info

Product

Resources

About